{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.0"},{"groupId":"OG001","value":"21.0"}]}],"title":"Nurse: 4 or more hours"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0"},{"groupId":"OG001","value":"29.0"}]}],"title":"Nurse: At least 3 hours but less than 4 hours"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.0"},{"groupId":"OG001","value":"23.0"}]}],"title":"Nurse: At least 2 hours but less than 3 hours"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.0"},{"groupId":"OG001","value":"11.0"}]}],"title":"Nurse: At least 1 hour but less than 2 hours"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0"},{"groupId":"OG001","value":"16.0"}]}],"title":"Nurse: Less than 1 hour"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.0"},{"groupId":"OG001","value":"22.0"}]}],"title":"Physician: 4 or more hours"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0"},{"groupId":"OG001","value":"21.0"}]}],"title":"Physician: At least 3 hours but less than 4 hours"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0"},{"groupId":"OG001","value":"26.0"}]}],"title":"Physician: At least 2 hours but less than 3 hours"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.0"},{"groupId":"OG001","value":"19.0"}]}],"title":"Physician: At least 1 hour but less than 2 hours"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0"},{"groupId":"OG001","value":"7.0"}]}],"title":"Physician: Less than 1 hour"}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"81"}],"units":"Participants"}],"description":"Physicians and nurses who administered rituximab were asked to answer the following question: \" If used in routine practice, on average, how much staff time could be saved with each administration of rituximab SC as compared to rituximab IV? (Please do not consider the time needed for the first IV administration, consider only the subsequent ones)\". The number of nurses that responded for both the IV and SC arms was 70. The number of physicians that responded for the IV and SC arms were 78 and 81 respectively.","groups":[{"description":"Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 0 Cycles 2-6: IV rituximab 500 mg/m\\^2 on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG000","title":"Part 2 : Rituximab IV 500 mg/m^2"},{"description":"Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 0 Cycles 2-6: SC rituximab 1600 mg on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG001","title":"Part 2: Rituximab SC 1600 mg"}],"paramType":"NUMBER","populationDescription":"All the physicians and nurses who responded to the questionnaire were included in the analysis.","reportingStatus":"POSTED","timeFrame":"Days 4-5 in Cycle 6","title":"Part 2: Physician/Nurse Opinion on Time Savings With Rituximab SC Compared With Rituximab IV","type":"SECONDARY","unitOfMeasure":"percentage of participants in the survey"}